Trinity Biotech plc is a publicly listed diagnostics company founded in 1992, headquartered in Bray, County Wicklow, Ireland, with global operations spanning the USA, Canada, and over 75 countries worldwide.
We specialise in the development, manufacture, and marketing of clinical diagnostic products for both clinical laboratory and point-of-care use
Our portfolio includes PCR and ELISA kits for infectious diseases, instruments for haemoglobinopathies and HbA1c testing, autoimmune disease diagnostics, and urinalysis.
As a NASDAQ-listed, commercial-stage biotech company, we are advancing the healthcare frontier by developing next-generation diagnostic solutions. In early 2024, we entered the wearable biosensor market, starting with continuous glucose monitoring (CGM), through the acquisition of Waveform Technologies.
Supported by a dedicated team of approximately 400 professionals, Trinity Biotech is internationally recognised for delivering high-quality, certified diagnostic tools — essential for accurate and reliable patient healthcare
Why Trinity Biotech?
– We develop trusted solutions that support diagnosis in infectious diseases, diabetes care, and autoimmune disorders.
– With manufacturing sites in Ireland and North America, and distribution networks in over 75 countries, we ensure high standards and fast delivery
– Our diagnostics are designed for precision, safety, and adherence to global health regulations.
– Building on our history of product excellence, we’re now expanding into advanced biosensor technologies for long-term health monitoring
Our Vision
From our beginnings in 1992, we have pursued a mission: to become a global leader in diagnostics—continually innovating to provide accurate, accessible, and impactful healthcare solutions.
